GeoVax Q2 2023 net loss widens to $5.93M ($0.22/sh); cash at $17.8M

GeoVax Labs, Inc.

Net loss for Q2 2023 was $5.93M ($0.22/sh) vs $2.24M ($0.18/sh) in Q2 2022.
R&D expenses jumped to $4.72M from $1.31M YoY, driven by clinical trial and manufacturing costs.
Cash and equivalents totaled $17.8M at June 30, 2023, down from $27.6M at Dec 31, 2022.
Initiated Phase 2 trial of GEO-CM04S1 in CLL patients; Gedeptin Phase 1/2 interim data showed no DLTs.
Expanded GEO-CM04S1 rights to include Mpox and smallpox; partnered with ABL for cGMP manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

GeoVax Labs, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended June 30, 2023.

View on SEC.gov

4 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-022895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.